Abstract |
The leucine7 to proline7 (Leu7Pro) polymorphism in preproneuropeptide Y (preproNPY) has been associated with accelerated atherosclerosis and type II diabetes, both of which are obesity-related diseases. The current study evaluated the impact of obesity on the disease risk linked to the Leu7Pro polymorphism of preproNPY in 393 elderly subjects. In 6 years follow-up, the polymorphism alone did not change the risk for abnormal glucose regulation, while obesity was associated with a significant 3-fold risk (odds ratio (OR) 2.95; 95% confidence interval (CI) 1.81-4.81, P<0.001) and the Leu7Pro polymorphism- obesity interaction, with a remarkable 12-fold risk (OR 12.33; 95% CI 1.18-128.35, P<0.05). The Leu7Pro polymorphism modified significantly the 10-year incidence of cardiovascular events, causing a 7.6-fold increase in the hazard ratio (HR 7.58; 95% CI 2.87-20.03, P<0.001) in the obese but not in the nonobese subjects. The results indicate that obesity may be a pivotal factor in multiplying the disease risk associated with the Leu7Pro polymorphism in preproNPY.
|
Authors | U Jaakkola, J Kallio, R J Heine, G Nijpels, L M T' Hart, J A Maassen, L M Bouter, C D A Stehouwer, J M Dekker |
Journal | European journal of clinical nutrition
(Eur J Clin Nutr)
Vol. 63
Issue 1
Pg. 150-2
(Jan 2009)
ISSN: 1476-5640 [Electronic] England |
PMID | 18043699
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Blood Glucose
- Neuropeptide Y
|
Topics |
- Aged
- Blood Glucose
(genetics, metabolism)
- Blood Pressure
(genetics)
- Body Mass Index
- Body Weight
(genetics)
- Cardiovascular Diseases
(genetics)
- Diabetes Mellitus
(etiology, genetics)
- Female
- Follow-Up Studies
- Glucose Tolerance Test
- Humans
- Male
- Neuropeptide Y
(genetics)
- Obesity
(complications, genetics)
- Polymorphism, Single Nucleotide
- Risk Factors
|